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Context: Testosterone deficiency prevalence increases with age, comorbidities, and obesity.
Objective: To inform clinical guidelines for testosterone deficiency management and development of
targets for nonpharmacologic intervention trials for these men, we determined serum testosterone in
never-smoking, lean men without select comorbidities in nationally representative surveys.
Design, Setting, Participants: We used cross-sectional data for never-smoking, lean men $20
years without diabetes, myocardial infarction, congestive heart failure, stroke, or cancer, without
use of hormone-influencing medications, and participated in morning sessions of National Health
and Nutrition Examination Survey (NHANES) III (phase I 1988–1991) or continuous NHANES
(1999–2004). By age, we determined median total testosterone (ng/mL) measured previously by a
Food and Drug Administration-approved immunoassay and median estimated free testosterone
concentration.
Results: In NHANES III, in never-smoking, lean men without comorbidities, median (25th, 75th
percentile) testosterone was 4% to 9% higher than all men—20 to 39 years: 6.24 (5.16, 7.51), 40 to 59:
5.37 (3.83, 6.49), and $60: 4.61 (4.01, 5.18). In continuous NHANES, in never-smoking, lean men
without comorbidities, levels were 13% to 24% higher than all men—20 to 39 years: 6.26 (5.32, 7.27), 40
to 59: 5.86 (4.91, 6.55), and $60: 4.22 (3.74, 5.73). In never-smoking, lean men without comorbidities,
median estimated free testosterone was similar to (NHANES III) or slightly higher than (continuous
NHANES) in all men.
Conclusions: These nationally representative data document testosterone levels (immunoassay) in
never-smoking, leanmenwithout select comorbidities 30 and 15 to 20 years ago. This information can be
incorporated into guidelines for testosterone deficiency management and used to develop targets for
nonpharmacologic intervention trials for testosterone deficiency.
Abbreviations: FDA, Food and Drug Administration; BMI, body mass index; NHANES, National Health and Nutrition Examination
Survey; CV, coefficients of variation; Q1, first quartile; Q3, third quartile.
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The prevalence of testosterone deficiency, also known as low testosterone, increases with age
[1], and testosterone concentration is lower in men who are obese [2, 3], and who have aging-
associated comorbidities such as diabetes [4]. We previously estimated that 8.4 million US
men aged 40 years old and older may have low total testosterone [1]. In that study, we used
testosterone ,3.00 ng/mL (,10.4 nmol/L) to define low testosterone, although cutpoints to
define low testosterone in aging men and men with certain comorbidities associated with
aging and obesity have not been agreed upon by authoritative bodies. Nevertheless, a large
number of men may experience the symptoms of low testosterone and be at risk for adverse
health consequences [4–6] and premature death [7–12].
Strategies to increase testosterone levels may include pharmacologic and non-
pharmacologic interventions. Testosterone (supplementation) therapy is widely available
in the United States, and manufacturers advertise it to consumers for alleviating the
symptoms of “low T” in aging men. Professional societies in the United States and Aus-
tralia generally recommend measuring serum testosterone concentration in men with
signs or symptoms of testosterone deficiency, but do not recommend screening asymp-
tomatic men for low testosterone [13–15]. The diagnosis of testosterone deficiency is
usually made based on the presence of signs and symptoms and consistently low tes-
tosterone levels. One guideline recommends against routine testosterone therapy for older
men with low testosterone and instead recommends individualized decision-making for
men 65 years and older who are symptomatic and have documented low testosterone [13].
Another guideline indicates that data do not currently justify testosterone therapy for
older men, often with chronic diseases, who have low circulating testosterone levels but
who do not have hypothalamic, pituitary, or testicular diseases [14]. In 2018, the US Food
and Drug Administration (FDA) required updates to testosterone product labeling to
“inform of possible increased risk of heart attack and stroke with use” and cautioned
against the unapproved use of testosterone to treat low levels due to aging, even in
symptomatic men [16].
Although observational studies suggest that men who are leaner, physically active,
and do not have diabetes have higher serum testosterone [2, 4, 17, 18], whether non-
pharmacologic strategies such as decreasing body fat, increasing lean mass, increasing
physical activity, and controlling diabetes are effective in raising serum testosterone in
older men and men with comorbidities and obesity have not been tested in large, phase 3
intervention trials.
Optimal circulating testosterone concentration for aging men, whether for use of tes-
tosterone therapy or for defining outcome in nonpharmacologic intervention trials aiming
to raise testosterone, has not been established. Clinical guidelines for men with hypo-
gonadism due to conditions of the hypothalamus, pituitary, and testes, typically indicate that
the target level during testosterone therapy is the age-specific lower range for eugonadal men
[14]. Given the possibility of adverse effects of testosterone therapy, targets for aging men
are needed.
Thus, to inform clinical guidelines for the diagnosis of laboratory testosterone deficiency
and its pharmacologic treatment, and to inform the development of target testosterone levels
for nonpharmacologic intervention trials for low testosterone in aging men, men with aging-
associated comorbidities, and obese men, we determined typical serum total testosterone
concentrations measured by immunoassay in never-smoking, lean men without select aging-
associated comorbidities by age in the US nationally representative National Health and
Nutrition Examination Surveys (NHANES) cross-sectionally at two calendar times ;30 and
15 to 20 years ago.
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1. Materials and Methods
A. Study Design and Population
We used previously measured serum testosterone concentrations and other data for men aged
20 years and older who participated in the morning sessions of NHANES III (1988–1991) or
continuous NHANES (1999–2004). Both were cross-sectional surveys that used multistage
stratified, clustered probability samples of the US population (civilian, noninstitutionalized);
no individual was intentionally sampled twice. Details on the sampling of participants from
NHANES III and from continuous NHANES for the measurement of serum testosterone were
previously published [19, 20]. Testosterone data were available for 1625 men in NHANES III
and 1508 men in continuous NHANES. We excluded men who were ,20 years old (NHANES
III, N 5 164; continuous NHANES, N 5 523); taking drugs (androgens, anabolic steroids, 5-
a-reductase inhibitors, and antigonadotropic agents) that affect serum concentration of hor-
mones (NHANES III,N5 2; continuousNHANES,N5 5); orwho had implausible testosterone
values [continuous NHANES, N5 2 (20.2, 50 ng/mL)]. In total, we included 672 non-Hispanic
white, 359 non-Hispanic black, 372Mexican-Americanmen, and 56men other race/ethnicity in
NHANES III, and 506 non-Hispanic white, 188 non-Hispanic black, 216 Mexican-American
men, and 68men of other race/ethnicity in continuousNHANES. In stratified analyses, we also
excluded men with missing information on weight, height, or waist circumference (NHANES
III, N 5 49; continuous NHANES, N 5 34).
B. Serum Testosterone Measurement
Serum samples from both surveys were previously assayed for testosterone concentration
using an FDA-approved competitive electrochemiluminescence immunoassay on the 2010
Elecsys autoanalyzer (Roche Diagnostics, Indianapolis, IN) in the laboratory of Dr. Nader
Rifai at Children’s Hospital in Boston, Massachusetts. The limit of detection of the assay is
0.02 ng/mL, and the functional sensitivity is 0.12 ng/mL [21]. The coefficients of variation
(CVs) were 5.9% and 5.8% at 2.5 and 5.5 ng/mL in quality control specimens in NHANES III
and was 4.8% for 21 duplicate specimens in continuous NHANES. We estimated free tes-
tosterone concentration [22] from measured testosterone, SHBG, and albumin (available
in the NHANES III and continuous NHANES public use databases); in general, free tes-
tosterone may be the better measure of androgen effect in individuals with abnormal
SHBG concentrations.
C. Other Variables
As part of the NHANES protocols, participants were interviewed, during which age, race,
cigarette smoking, and history of chronic diseases—diabetes, myocardial infarction, stroke,
congestive heart failure, or cancer—were assessed, and underwent a physical examination,
during which height, weight, and waist circumference were measured. Medications used in
the last 30 days were ascertained during the interview, and when available, confirmed by
review of the participants’ medication containers. We calculated body mass index (BMI) as
weight (kilograms) divided by the square of height (meters). We defined never smokers as
men who smoked ,100 cigarettes over their lifetimes.
D. Statistical Analysis
We applied sampling weights and determined the mean and SE (Taylor series robust variance
estimation), and the 10th, 25th (first quartile), 50th (median), 75th (third quartile), and 90th
percentiles of total and free testosterone concentration among men 20 to 39 years, 40 to 59
years, and$60 years old overall and among leanmen (BMI, 25 kg/m2 andWC, 102 cm),men
without select major aging-associated comorbidities (diabetes, heart attack, congestive heart
failure, stroke, cancer), and men who were lean and did not have select major aging-associated
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comorbidities. We repeated these analyses in men who were never smokers (in NHANES III,
current smokers had higher and former smokers had lower serum testosterone than never
smokers after multivariable adjustment [17]). Finally, we repeated all of these analyses
separately among non-Hispanic white, non-Hispanic black, and Mexican-American men.
We also modeled total testosterone concentrations by weighted LOESS (locally estimated
scatterplot smoothing) linear regression, so that typical concentration could be determined
for any given adult age.
2. Results
A. Total Testosterone
Median (25th, 75th percentile) testosterone concentrations (ng/mL) in men ages 20 to 39, 40
to 59, and $60 years old were 5.99 (4.84, 7.31), 4.86 (3.79, 6.18), and 4.35 (3.25, 5.36), re-
spectively, in NHANES III [medians in Table 1; means, SEs, and percentiles in Supplemental
Table 1 (supplemental tables are deposited in [23])], and 5.42 (4.34, 6.85), 4.45 (3.39, 5.90),
and 3.92 (2.74, 5.14), respectively, in continuous NHANES (Table 1; Supplemental Table 2
[23]). In lean men without comorbidities, across all three age groups, median serum tes-
tosterone concentrations were higher compared with all men in both NHANES III (Table 1;
Supplemental Table 1 [23]) and continuous NHANES (Table 1; Supplemental Table 2 [23]).
After restricting to never-smoking men, those who were lean and without comorbidities had
median serum testosterone concentrations that were higher (4% to 9% in NHANES III and
13% to 24% in continuous NHANES) than in all men, but generally lower than when in-
cluding ever smokers; concentrations were 6.24 (5.16, 7.51), 5.37 (3.83, 6.49), and 4.61 (4.01,
5.18), respectively, in NHANES III (Table 1; Supplemental Table 3 [23]), and 6.26 (5.32, 7.27),
5.86 (4.91, 6.55), and 4.22 (3.74, 5.73), respectively, in continuous NHANES (Table 1;
Supplemental Table 4 [23]). Modeled distributions of total testosterone concentration by age
among each subpopulation are shown in Figs. 1 (NHANES III) and 2 (continuous NHANES).
Table 1. Median Total Testosterone Concentration (ng/mL) by Age Among All Men and Among Men
Without Health States That Influence Testosterone Level in NHANES III (1988–1994) and in Continuous
NHANES (1999–2004)
Age Group, y
20–39 40–59 601
NHANES III
All men 5.99 4.86 4.35
Lean mena 6.75 5.75 4.78
Men without comorbiditiesb 6.00 4.93 4.45
Lean men without comorbidities 6.77 5.85 4.92
Never-smoking men 5.52 4.78 4.44
Never-smoking lean men 6.24 5.36 4.36
Never-smoking men without comorbidities 5.51 4.79 4.48
Never-smoking lean men without comorbidities 6.24 5.37 4.61
Continuous NHANES
All men 5.42 4.45 3.92
Lean mena 6.55 5.76 4.92
Men without comorbiditiesb 5.45 4.61 4.09
Lean men without comorbidities 6.57 5.85 5.06
Never-smoking men 5.19 4.43 4.08
Never-smoking lean men 6.27 5.84 4.37
Never-smoking men without comorbidities 5.19 4.48 4.15
Never-smoking lean men without comorbidities 6.26 5.86 4.22
To convert testosterone to nmol/L, multiple values by 3.4672.
aBMI , 25 kg/m2 and waist circumference , 102 cm.
bNo diabetes, myocardial infarction, congestive heart failure, stroke, or cancer.
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B. Free Testosterone
Median (25th, 75th percentile) free testosterone concentrations (ng/mL) in men ages 20 to 39,
40 to 59, and $60 years old were 0.13 (0.11, 0.15), 0.10 (0.08, 0.12), and 0.07 (0.05, 0.09),
respectively, in NHANES III (Table 2; Supplemental Table 5 [23]), and 0.12 (0.10, 0.14), 0.09
(0.07, 0.11), and 0.06 (0.05, 0.08), respectively, in continuous NHANES (Table 2; Supple-
mental Table 6 [23]). In lean men without comorbidities, across all three age groups, median
free testosterone concentrations were similar to all men in NHANES III (Table 2; Supple-
mental Table 5) but higher than in all men in continuous NHANES (Table 2; Supplemental
Figure 1. Circulating testosterone concentration across age: overall and in never-smoking
men and men without aging-associated comorbidities, in NHANES III (1988–1991).
Figure 2. Circulating testosterone concentration across age: overall and in never-smoking
men and men without aging-associated comorbidities, in NHANES continuous (1999–2004).
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Table 6 [23]). After restricting to never-smoking men, in NHANES III, those who were lean
and without comorbidities hadmedians that were similar to all men and when including ever
smokers; free testosterone concentrations were 0.13 (0.10, 0.14), 0.11 (0.08, 0.13), and 0.07
(0.06, 0.08), respectively (Table 2; Supplemental Table 7 [23]). After restricting to never-
smoking men, in continuous NHANES, those who were lean and without comorbidities had
medians that were higher compared with all men, but similar to when including ever
smokers; free testosterone concentrations were 0.13 (0.11, 0.16), 0.11 (0.09, 0.12), and 0.07
(0.05, 0.09), respectively (Table 2; Supplemental Table 8 [23]). Modeled distributions of free
testosterone concentration by age among each subpopulation are shown in Figs. 3 (NHANES
III) and 4 (continuous NHANES).
C. By Race/Ethnicity
C-1. Total testosterone
Across all three age groups, patterns for total testosterone were similar by race/ethnicity with
concentrations generally being higher in lean men without comorbidities than in all men in
both NHANES III (medians in Table 3; distributions in Supplemental Table 9 [23]) and
continuous NHANES (Table 3; Supplemental Table 10 [23]) and generally being higher in
never-smoking leanmenwithout comorbidities than in all men in bothNHANES III (Table 3;
Supplemental Table 11 [23]) and continuousNHANES (Table 3; Supplemental Table 12 [23]).
C-2. Free testosterone
Across all three age groups, in NHANES III, patterns for free testosterone were similar by
race/ethnicity with concentrations in leanmenwithout comorbidities generally being equal to
Table 2. Median Free Testosterone Concentration (ng/mL) by Age Among All Men and Among Men
Without Health States That Influence Testosterone Level in NHANES III (1988–1994) and in Continuous
NHANES (1999–2004)
Age Group, y
20–39 40–59 601
NHANES III
All men 0.13 0.10 0.07
Lean mena 0.14 0.13 0.11
Men without comorbiditiesb 0.13 0.10 0.07
Lean men without comorbidities 0.13 0.11 0.07
Never-smoking men 0.12 0.10 0.07
Never-smoking lean men 0.13 0.11 0.07
Never-smoking men without comorbidities 0.12 0.10 0.07
Never-smoking lean men without comorbidities 0.13 0.11 0.07
Continuous NHANES
All men 0.12 0.09 0.06
Lean mena 0.13 0.10 0.06
Men without comorbiditiesb 0.12 0.09 0.06
Lean men without comorbidities 0.13 0.10 0.07
Never-smoking men 0.12 0.09 0.07
Never-smoking lean men 0.13 0.11 0.08
Never-smoking men without comorbidities 0.12 0.09 0.07
Never-smoking lean men without comorbidities 0.13 0.11 0.07
To convert free testosterone to nmol/L, multiple values by 3.4672.
aBMI , 25 kg/m2 and waist circumference , 102 cm.
bNo diabetes, myocardial infarction, congestive heart failure, stroke, or cancer.
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all men (Table 4; Supplemental Table 13 [23]). In contrast, in continuous NHANES, patterns
for free testosterone differed by race/ethnicity with concentrations in lean men without
comorbidities being higher than in all men among non-Hispanic white men and being the
same as in all men among Mexican-American men; no discernable pattern was present in
non-Hispanic black men (Table 4; Supplemental Table 14 [23]). No patterns for free tes-
tosterone were discernable by racial/ethnic group in never-smoking lean men without
comorbidities compared with all men in either NHANES III (Table 4; Supplemental Table 15
[23]) or continuous NHANES (Table 4; Supplemental Table 16 [23]).
Figure 4. Circulating free testosterone concentration across age: overall and in never-
smoking men and men without aging-associated comorbidities, in NHANES continuous
(1999–2004).
Figure 3. Circulating free testosterone concentration across age: overall and in never-
smoking men and men without aging-associated comorbidities, in NHANES III (1988–1991).
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3. Discussion
Irrespective of whether aging men, men with aging-associated comorbidities, or obese men
with low testosterone are managed via testosterone supplementation, weight reduction/
lifestyle modifications, or other strategies, definitions of low testosterone and target tes-
tosterone levels are needed. Here, we provided needed information for these guidelines and
targets on typical serum total and free testosterone concentrations that were measured by
immunoassay in normal weight, never-smoking men without comorbidities from US na-
tionally representative surveys conducted 30 and 15 to 20 years ago. Given the decline in
testosterone with age, whether the target level for an older man should be the same as for a
younger man is unclear. Thus, we also provided levels among younger, middle-aged, and
older men, as well as modeled curves, so that typical concentrations in healthy men could be
determined at any adult age. We also provided levels by race/ethnicity, given reported racial/
ethnic differences in concentrations [19, 20, 24].
The risks and benefits of testosterone therapy have been reviewed comprehensively in
clinical guidelines [13, 15]. From the public health perspective, use of nonpharmacologic
Table 3. Distribution of Total TestosteroneConcentration (ng/mL) by Age andRace AmongAllMen and
AmongMenWithout Health States That Influence Testosterone Level in NHANES III (1988–1994) and in
Continuous NHANES (1999–2004)
Age Group (y)
20–39 40–59 601
NHANES III
Non-Hispanic white
All men 6.04 4.81 4.43
Lean men without comorbiditiesa 6.93 5.72 5.13
Never-smoking men 5.38 4.79 4.69
Never-smoking lean men without comorbidities 5.93 5.11 4.79
Non-Hispanic black
All men 6.23 5.75 4.29
Lean men without comorbiditiesa 7.05 5.94 4.88
Never-smoking men 5.80 5.30 3.44
Never-smoking lean men without comorbidities 7.06 6.23 3.37
Mexican-American
All men 5.84 4.31 4.20
Lean men without comorbiditiesa 6.73 6.01 3.92
Never-smoking men 5.85 4.21 4.14
Never-smoking lean men without comorbidities 6.72 5.40 4.16
Continuous NHANES
Non-Hispanic white
All men 5.20 4.38 3.85
Lean men without comorbiditiesa 6.45 5.74 5.11
Never-smoking men 4.86 4.34 4.06
Never-smoking lean men without comorbidities 5.96 5.83 4.19
Non-Hispanic black
All men 6.44 5.83 4.26
Lean men without comorbiditiesa 7.93 6.44 4.93
Never-smoking men 6.24 5.72 3.91
Never-smoking lean men without comorbidities 8.57 4.31 5.69
Mexican-American
All men 5.45 4.33 3.98
Lean men without comorbiditiesa 6.22 5.95 3.77
Never-smoking men 5.24 4.26 3.48
Never-smoking lean men without comorbidities 5.86 5.85 5.02
To convert testosterone to nmol/L, multiple values by 3.4672.
aBMI, 25 kg/m2 and waist circumference, 102 cm and no diabetes, myocardial infarction, congestive heart failure,
stroke, or cancer.
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strategies to normalize testosterone levels in older men with comorbidities may be preferable
to testosterone supplementation because such strategies may benefit overall health and not
be associated with adverse effects. Such randomized intervention trials have not been
conducted on a large scale, so it remains unclear whether the published data indicating that
leaner men who have higher serum testosterone than men with more body fat and less lean
mass would translate into increases in testosterone if men with more fat and less lean mass
were to lose fat and gain lean mass [25].
We provided distributions of total and free testosterone for men participating only in the
morning sessions of phase 1 of NHANES in 1988 to 1991 or continuous NHANES in 1999 to
2004 given the diurnal variation in testosterone in men [26]. The CVs for the NHANES III
samples that were assayed at both time points were 6.3% for testosterone, and 5.3% for
SHBG, which was used in the calculation of free testosterone. Despite being measured at
different times, the mean concentrations among all men at the two time points from our prior
work (without the exclusions in the current work) were similar at 5.37 and 5.34 (P5 0.75) for
testosterone and 0.099 and 0.097 (P 5 0.67) for free testosterone in NHANES III and
Table 4. Distribution of Free Testosterone Concentration (ng/mL) by Age and Race Among All Men and
AmongMenWithout Health States That Influence Testosterone Level in NHANES III (1988–1994) and in
Continuous NHANES (1999–2004)
Age Group (y)
20–39 40–59 601
NHANES III
Non-Hispanic white
All men 0.13 0.10 0.07
Lean men without comorbiditiesa 0.13 0.10 0.07
Never-smoking men 0.11 0.10 0.07
Never-smoking lean men without comorbidities 0.12 0.11 0.07
Non-Hispanic black
All men 0.13 0.10 0.07
Lean men without comorbiditiesa 0.14 0.10 0.07
Never-smoking men 0.13 0.10 0.06
Never-smoking lean men without comorbidities 0.15 0.10 0.05
Mexican-American
All men 0.13 0.09 0.07
Lean men without comorbiditiesa 0.13 0.11 0.07
Never-smoking men 0.13 0.09 0.07
Never-smoking lean men without comorbidities 0.13 0.11 0.07
Continuous NHANES
Non-Hispanic white
All men 0.12 0.09 0.06
Lean men without comorbiditiesa 0.13 0.10 0.07
Never-smoking men 0.12 0.09 0.06
Never-smoking lean men without comorbidities 0.12 0.10 0.06
Non-Hispanic Black
All men 0.14 0.10 0.07
Lean men without comorbiditiesa 0.16 0.10 0.08
Never-smoking men 0.13 0.11 0.06
Never-smoking lean men without comorbidities 0.17 0.07 0.09
Mexican-American
All men 0.12 0.09 0.07
Lean men without comorbiditiesa 0.12 0.10 0.07
Never-smoking men 0.12 0.08 0.06
Never-smoking lean men without comorbidities 0.12 0.09 0.07
To convert free testosterone to nmol/L, multiple values by 3.4672.
aBMI, 25 kg/m2 and waist circumference, 102 cm and no diabetes, myocardial infarction, congestive heart failure,
stroke, or cancer.
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continuous NHANES, respectively [20]. The low CVs and similar means at the two time
points suggest the comparability of the assay despite being performed at different times for
the two surveys. In the current analysis, in lean men without select comorbidities, mean
(median) total testosterone concentrations were within 5% between NHANES III and con-
tinuous NHANES: 22.2% (13.0%), 24.6% (0.0%), and 22.7% (22.8%) in men 20 to 39, 40 to
49, and 601 years old. Thus, any differences in testosterone levels between the two surveys
after excluding men who had excess adiposity, comorbidities, and ever smoked (the preva-
lences of which have changed over calendar time) are unlikely solely due to assay variability
over time, and more likely due to secular differences in prevalences in other factors that
influence testosterone or due to chance variability.
The major strengths of this analysis are that we used nationally representative data,
enhancing the generalizability of the estimated testosterone concentrations to US men, and
the data were from established surveys that have a wealth of data, allowing us to restrict to
subpopulations so that we could obtain what could be considered typical testosterone con-
centrations in healthy men. Although other studies have previously reported on age-specific
testosterone levels in healthy men, these were not representative general populations of
healthy men (e.g., blood donors, sports club members [27]).
Several aspects of this study warrant discussion. First, a priori, we considered never
smoking, lean men without histories of select, common aging-associated comorbidities to be
those with typical testosterone levels for healthy men. We did not exclude men with less
common, nonaging comorbidities, such as men with HIV who are immunosuppressed and
more likely to have lower testosterone [28]. Second, we noted small numbers ofmen in the two
analytic populations who had serum testosterone concentrations that were near the limit of
detection of 0.02 ng/mL (e.g., testosterone , 0.1 ng/mL: NHANES III, N 5 5; continuous
NHANES, N5 4); the number of thesemenwas lower when restricting to normal weightmen
without comorbidities (NHANES III, N 5 1; continuous NHANES, N 5 0). Although the
reasons for these low levels—congenital or acquired or laboratory error—are not known, we
presume them to be representative of population-level sampling. Whether these men with
such low testosterone would benefit from interventions directed at increasing testosterone
via lifestyle modification is not known. Third, for quantitating testosterone concentration, we
used the Elecsys Testosterone Immunoassay (Roche Diagnostics), which was FDA approved
and in wide clinical use. The method was standardized by isotope dilution gas chromatog-
raphy mass spectrometry [21]. The functional sensitivity (limit of quantitation) was well
below the often used cutpoint for low testosterone of 3.0 ng/mL. Although mass spectrometry
may produce more accurate quantitation of sex steroid hormones and is considered to be the
gold standard, that assay method is not currently FDA approved for clinical use [29]. The
values we report may be assay method-dependent. Fourth, given that the biologically
available fraction of serum testosterone is free testosterone, rather than SHBG or albumin-
bound testosterone, we also determined typical free testosterone in never-smoking, lean men
without comorbidities. SHBG is well recognized to be lower in obese men, which helps
maintain free testosterone level. Thus, men with low total testosterone may have normal
range free testosterone. We estimated the free fraction using each man’s measured SHBG
and albumin. Fifth, although we used nationally representative data, we were only able to
study the prevalent racial/ethnic groups at the time of the two surveys. Sixth, because we
used existing data, sample sizes were small in some subgroups. Finally, although the data we
provide could be used to define population-based low levels by age and/or age and race
distributions, such cutpoints would not necessarily map to the extent and severity of health
states influenced by testosterone. In this study, we did not evaluate whether the levels of total
and free testosterone in the never-smoking, lean men without comorbidities are associated
with a lower likelihood of symptoms associated with low testosterone, such as fatigue, lower
libido, and erectile dysfunction, information also needed for revising clinical guidelines and
establishing target testosterone levels.
In summary, we determined typical serum testosterone concentrations that were measured
by immunoassay in healthy, never-smoking normal weight men representative of the US
1768 | Journal of the Endocrine Society | doi: 10.1210/js.2019-00151
population cross-sectionally at two calendar times 30 and 15 to 20 years ago. We expect that
these data provide some of the information that is needed to: (i) refine the definition of tes-
tosterone deficiency in older men and to inform its pharmacologic treatment, and (ii) establish
target total serum testosterone levels for nonpharmacologic intervention trials for men with
testosterone deficiency associated with aging, aging-associated comorbidities, and obesity.
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